Showing 2371-2380 of 3138 results for "".
- Restylane® Refyne and Restylane® Defyne Show Lasting Natural Benefit in Phase 4 Studieshttps://modernaesthetics.com/news/restylane-refyne-and-restylane-defyne-show-lasting-natural-benefit-in-phase-4-studies/2472251/Two Phase 4 clinical studies of Restylane® Refyne and Restylane® Defyne show that the natural-looking results last. Specifically, the Natural Expression study found that naturalness in facial expressions was at least main
- Breaking Business News: Apax Partners to Acquire Syneronhttps://modernaesthetics.com/news/breaking-business-news-apax-partner-to-acquire-syneron/2472253/An affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for $11.00 per share in cash in a transaction valued at approximately $397 million. The per share acquisition price represe
- Zeltiq Showcases CoolAdvantage Petite Applicator at AAD Annual Meetinghttps://modernaesthetics.com/news/zeltiq-showcases-cooladvantage-petite-applicator-at-aad-annual-meeting/2472261/ZELTIQ® Aesthetics is showcasing the CoolAdvantage Petite™ applicator at the American Academy of Dermatology Annual Meeting (AAD) in Orlando. The CoolAdvantage technology is the only non-invasive fat removal technology cleared by the
- Aesthetics Wire Exclusive: AAFPRS Survey Shows Combination Facial Plastic Surgery Treatment Requests Are Soaringhttps://modernaesthetics.com/news/aesthetics-wire-exclusivecombination-facial-plastic-surgery-treatment-requests-soaring/2472289/Combination therapies reign supreme, according to the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) 2016 statistics. In 2016, 66 percent of facial plastic surgeons reported performing combined non-surgical procedures in the same
- Update: Revance Starts Phase III Studies on RT002 for Frown Lineshttps://modernaesthetics.com/news/revance-starts-phase-iii-studies-on-rt002-for-frown-lines/2472297/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials
- Revealed: What A Girl Wants in a Plastic Surgeonhttps://modernaesthetics.com/news/revealed-what-a-girl-wants-in-a-plastic-surgeon/2472307/Nearly half of all female plastic surgery patients have no preference when it comes to the gender of their cosmetic surgeon, a new study show. Specifically, the report, published in Aesthetic Surgery Journal</
- AAD Selects ContextMedia:Health as Patient Education Affinity Partnerhttps://modernaesthetics.com/news/aad-selects-contextmediahealth-as-patient-education-affinity-partner/2472318/ContextMedia:Health is now an Affinity Partner with the American Academy of Dermatology (AAD). The partnership offers ContextMedia:Health's suite of digital technology to the AAD's U.S. members at no cost. The agreement also bring
- Recently Retired American Academy of Facial Plastic and Reconstructive Surgery CEO Receives AMA Lifetime Achievement Awardhttps://modernaesthetics.com/news/recently-retired-american-academy-of-facial-plastic-and-reconstructive-surgery-ceo-receives-ama-lifetime-achievement-award/2472317/The American Medical Association (AMA) has presented the Medical Executive Lifetime Achievement Award to Stephen C. Duffy, former executive vice president and CEO of the American Academy of Facial Plastic and Reconstructive Sur
- Syneron Candela's Profound SubQ FDA Approved to Improve Cellulitehttps://modernaesthetics.com/news/syneron-candelas-profound-subq-fda-approved-to-improve-cellulite/2472321/Syneron Candela received FDA 510(k) clearance for Profound when using the SubQ handpiece and cartridge to improve the appearance of cellulite in patients with Fitzpatrick skin types I-III, as supported by long term data (6 months). A recent multi-center clinical study of Profound sh
- FDA Clears Cutera truFlex® for Muscle Rehab, Recovery, and Post-Surgical Usehttps://modernaesthetics.com/news/fda-clears-cutera-truflex-for-muscle-rehab-recovery-and-post-surgical-use/2485023/Cutera, Inc. has announced that its truFlex® muscle stimulation system has received expanded US Food and Drug Administration (FDA) clearances for use in rehabilitation, recovery, and muscle wellness applications. Originally cleared for aesthetic body contouring, the system can now be used to stre